- Home
- EQ vs AIRI Comparison
EQ vs AIRI Comparison
Compare EQ & AIRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- AIRI
- Stock Information
- Founded
- EQ 2017
- AIRI 1979
- Country
- EQ United States
- AIRI United States
- Employees
- EQ N/A
- AIRI N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- AIRI Military/Government/Technical
- Sector
- EQ Health Care
- AIRI Industrials
- Exchange
- EQ Nasdaq
- AIRI Nasdaq
- Market Cap
- EQ 24.8M
- AIRI 20.2M
- IPO Year
- EQ 2018
- AIRI N/A
- Fundamental
- Price
- EQ $0.74
- AIRI $4.52
- Analyst Decision
- EQ Buy
- AIRI
- Analyst Count
- EQ 2
- AIRI 0
- Target Price
- EQ $5.00
- AIRI N/A
- AVG Volume (30 Days)
- EQ 304.3K
- AIRI 67.9K
- Earning Date
- EQ 11-13-2024
- AIRI 11-14-2024
- Dividend Yield
- EQ N/A
- AIRI N/A
- EPS Growth
- EQ N/A
- AIRI N/A
- EPS
- EQ N/A
- AIRI N/A
- Revenue
- EQ $45,914,000.00
- AIRI $53,657,000.00
- Revenue This Year
- EQ N/A
- AIRI $9.26
- Revenue Next Year
- EQ N/A
- AIRI $8.73
- P/E Ratio
- EQ N/A
- AIRI N/A
- Revenue Growth
- EQ 7.70
- AIRI 3.31
- 52 Week Low
- EQ $0.48
- AIRI $2.89
- 52 Week High
- EQ $3.25
- AIRI $9.44
- Technical
- Relative Strength Index (RSI)
- EQ 40.86
- AIRI 32.37
- Support Level
- EQ $0.66
- AIRI $4.25
- Resistance Level
- EQ $0.77
- AIRI $6.18
- Average True Range (ATR)
- EQ 0.08
- AIRI 0.35
- MACD
- EQ -0.01
- AIRI -0.18
- Stochastic Oscillator
- EQ 26.09
- AIRI 8.33
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
About AIRI Air Industries Group
Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.